World Journal of
Pharmaceutical and Life Sciences

LC–MS–GUIDED ANALYTICAL AND THERAPEUTIC PROFILING OF PAZOPANIB IN RENAL CARCINOMA CELL LINE MODELS

Nada Ahmed Al Amoodi*, Dr. Syed Ahmed Hussain, Ghousia Begum, Fariya Sultana, Bilquis Begum, Somabatthini Shruthi, Ayesha Ayub Khan, Muskan Khatoon

ABSTRACT

This study evaluates the in vitro antiproliferative and apoptotic effects of Pazopanib in comparison with Sunitinib in renal cell carcinoma (RCC) cell models (786-O, Caki-1, A498). A five-assay panel quantified both cell viability and cytotoxicity endpoints. Pazopanib showed moderate inhibition of cell growth, with viability and ATP activity reduced to 80% and 83%, respectively, compared to the vehicle control, while Sunitinib demonstrated stronger antiproliferative effects (~45%). Apoptosis and cytotoxicity assays revealed that Pazopanib induced 22% apoptosis, 1.8-fold caspase-3/7 activation, and 21% LDH release, reflecting modest apoptotic potential relative to Sunitinib (57%, 3.5-fold, and 58%, respectively). These results indicate that Pazopanib exerts cytostatic rather than cytotoxic activity, primarily through VEGFR and PDGFR blockade leading to angiogenesis inhibition and cell growth suppression, without inducing extensive apoptosis. The findings support Pazopanib’s role as a well-tolerated antiangiogenic agent for RCC with limited direct tumoricidal action in vitro.

[Full Text Article]   [Download Certificate]